Eric Ostertag - 11 Oct 2021 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 11 Oct 2021
Net transactions value: +$169,504
Form type: 4
Filing time: 13 Oct 2021, 18:59:12 UTC
Previous filing: 05 Oct 2021
Next filing: 10 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Options Exercise	$169,504	+18,525	+2.7%	$9.15	696,422	11 Oct 2021	Direct	F1
holding	PSTX	Common Stock						3,669,376	11 Oct 2021	See footnote	F2
holding	PSTX	Common Stock						3,367,506	11 Oct 2021	See footnote	F3
holding	PSTX	Common Stock						629,194	11 Oct 2021	See footnote	F4
holding	PSTX	Common Stock						961,445	11 Oct 2021	See footnote	F5
holding	PSTX	Common Stock						160,696	11 Oct 2021	See footnote	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Options Exercise	$0	-18,525	-2.4%	$0.000000	740,995	11 Oct 2021	Common Stock	18,525	$9.15	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 2,482 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021.
F2	The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F3	The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F4	The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F5	The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
F6	The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
F7	12.5% of the shares originally subject to the stock option vested and became exercisable on August 4, 2021, and the remaining shares vest in 42 equal monthly installments thereafter.